In a moment that reveals how medicine often races ahead of its own evidence, US federal regulators have acknowledged that testosterone therapy for women — widely prescribed off-label for sexual dysfunction and low libido — lacks the scientific foundation needed to guide safe, confident clinical practice. The call for more rigorous research is not a condemnation of the therapy, but a reckoning with the distance between what patients need, what doctors are doing, and what science can actually confirm. It is a reminder that in medicine, good intentions and incomplete evidence can coexist in ways